Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.41 |
| ▸ | WNT3A | P56704 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3739676 | 0.91 | ACHE (0.56) | ACHECTNNB1WNT3AALDH1A1PAX8 | |
| SCHEMBL3744520 | 0.89 | ACHE (0.46) | ACHECTNNB1WNT3AALDH1A1DAO | |
| SCHEMBL3740354 | 0.88 | ACHE (0.45) | ACHECTNNB1WNT3AALDH1A1PAX8 | |
| SCHEMBL3747714 | 0.87 | DAO (0.43) | ALDH1A1PPARDDAO | |
| SCHEMBL3736215 | 0.87 | ACHE (0.46) | ACHEALDH1A1PPARDCSF1RPPARA | |
| SCHEMBL3743868 | 0.85 | PDE4A (0.55) | ACHECTNNB1WNT3AALDH1A1PAX8 | |
| SCHEMBL3741591 | 0.84 | PPARD (0.41) | ALDH1A1PPARDDAO | |
| SCHEMBL3743226 | 0.83 | PIM1 (0.42) | PPARDFFAR1DAO | |
| SCHEMBL3740298 | 0.82 | PPARD (0.41) | PPARDDAO | |
| SCHEMBL3732785 | 0.80 | PDE4D (0.62) | ACHEDAOPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | ACHE 3848/4885CTNNB1 2968/4885WNT3A 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.